Use of sodium formate in preparation of an anti-infective drug

Patent metadata

Field	Value
Publication number	US-2025041254-A1
Application number	US-202218717426-A
Country	US
Kind code	A1
Filing date	Dec 15, 2022
Priority date	Aug 24, 2022
Publication date	Feb 6, 2025
Grant date	—

Abstract

The present invention belongs to the technical field of biological medicine, and specifically relates to use of sodium formate in preparation of an anti-infective drug. The present invention has found through research that sodium formate can significantly increase the sensitivity of a bacterium to an antibiotic, so that the antibiotic that is originally ineffective or inefficient against a pathogenic bacterium becomes effective or efficient, thereby killing the bacterium and achieving an anti-infective effect. Sodium formate and an antibiotic are further prepared into an anti-infective composition, so that on the one hand, a significant anti-infective effect can be achieved under the condition of a low-concentration antibiotic, and on the other hand, the decreased use amount of the antibiotic can also significantly reduce the likelihood of a bacterium developing drug resistance; and sodium formate has been widely used in food and medicine with high safety.

First claim

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . An anti-infective composition, comprising sodium formate and an aminoglycoside antibiotic.

8 . The composition according to claim 7 , wherein the aminoglycoside antibiotic is one or more of micronomicin, gentamicin, and amikacin.

9 . The composition according to claim 7 , wherein a mass ratio of the sodium formate to the antibiotic is (0.088-90.67):1.

10 . An anti-infective drug, comprising the anti-infective composition according to claim 7 .

11 . The composition according to claim 8 , wherein a mass ratio of the sodium formate to the antibiotic is (0.088-90.67):1.

12 . An anti-infective drug, wherein the anti-infective drug comprises the anti-infective composition according to claim 8 .

13 . An anti-infective drug, wherein the anti-infective drug comprises the anti-infective composition according to claim 9 .

14 . An anti-infective drug, wherein the anti-infective drug comprises the anti-infective composition according to claim 11 .

15 . An anti-infection method, comprising:
combining sodium formate with an antibiotic, to enhance sensitivity of a bacterium to the antibiotic by a synergistic effect of the sodium formate and the antibiotic, thereby killing the bacterium and achieving an anti-infective effect.

16 . The method according to claim 15 , wherein the antibiotic is an aminoglycoside antibiotic.

17 . The method according to claim 16 , wherein the aminoglycoside antibiotic is one or more of micronomicin, gentamicin, and amikacin.

18 . The method according to claim 15 , wherein the bacterium is an antibiotic-sensitive or clinically drug-resistant Gram-negative bacterium.

19 . The method according to claim 18 , wherein the bacterium is Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Edwardsiella tarda, Vibrio , or Staphylococcus aureus.

Assignees

• Univ Sun Yat Sen

Inventors

• Li Hui
• Peng Bo
• Peng Xuanxian
• Kuang Sufang

Classifications

• A61K31/7036

  having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/19 Primary

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title